Disorders of MicroRNAs in Peripheral Blood Mononuclear Cells: As Novel Biomarkers of Ankylosing Spondylitis and Provocative Therapeutic Targets

Biomed Res Int. 2015:2015:504208. doi: 10.1155/2015/504208. Epub 2015 Jul 26.

Abstract

Background: MicroRNAs can potentially regulate every aspect of cellular activity. In this study, we investigated whether AS pathogenesis involves microRNAs disorders.

Result: The expression of 2 microRNAs, hsa-miR-126-3p and hsa-miR-29a, was significantly lower in active AS group before etanercept therapy than in control group. Marched fold changes of them were 3.76 and 16.22. Moreover, expressions of hsa-miR-126-3p and hsa-miR-29a were dramatically upregulated after 12-weeks etanercept treatment. Fold changes were 2.20 and 3.18. All regulations of microRNAs expression mentioned before were statistically significant (fold change >2 and P < 0.05). The expression disorders of the 2 microRNAs did not statistically significantly correlated with BASDAI, CRP, and ESR.

Conclusion: AS pathogenesis involved dysregulation of microRNAs. Hsa-miR-126-3p and hsa-miR-29a will probably become the potential biomarkers and provocative therapeutic targets of AS.

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Female
  • Genetic Diseases, Inborn / diagnosis*
  • Genetic Diseases, Inborn / genetics*
  • Genetic Diseases, Inborn / therapy
  • Genetic Markers / genetics
  • Genetic Therapy
  • Humans
  • Leukocytes, Mononuclear / metabolism
  • Male
  • MicroRNAs / genetics*
  • Middle Aged
  • Molecular Targeted Therapy
  • Reproducibility of Results
  • Sensitivity and Specificity
  • Spondylitis, Ankylosing / diagnosis*
  • Spondylitis, Ankylosing / genetics*
  • Spondylitis, Ankylosing / therapy

Substances

  • Genetic Markers
  • MIRN126 microRNA, human
  • MIRN29a microRNA, human
  • MicroRNAs